{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:50:52Z","timestamp":1773291052086,"version":"3.50.1"},"reference-count":19,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate agreement of the updated European League Against Rheumatism and European Scleroderma Trials and Research group (EUSTAR) recommendations for treatment of systemic sclerosis (SSc) among international experts. In addition, to determine factors that might influence agreement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Level of agreement (10-point scale: 0 = not at all, 10 = completely agree) and local drug availability (yes\/no) were assessed using an online survey. The Web link to the survey was shared with 481 unique e-mail addresses and SSc networks (Scleroderma Clinical Trials Consortium, Australian Scleroderma Interest Group, International Systemic Sclerosis Inception Cohort). Level of agreement was compared between subgroups stratified for participant characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>In total, 263 experts participated, of whom n = 209 (79%) completed each single item. The majority were rheumatologists (n = 200, 76%) working in Europe (n = 185; 71%); 59% (n = 156) were EUSTAR members; and 57% (n = 151) had &gt; 10 years of clinical experience. Overall level of agreement was high (mean 8.0, SD 2.5). The 3 highest mean agreements included (1) angiotensin-converting enzyme inhibitors for scleroderma renal crisis (9.2, SD 2.1); (2) blood pressure control in SSc-patients treated with corticosteroids (9.0, SD 2.2); (3) proton pump inhibitors to prevent reflux complications (9.0, SD 2.2). The 3 lowest mean agreements included (1) fluoxetine for Raynaud phenomenon (RP; 4.6, SD 2.8); (2) hematopoietic stem cell transplantation (HSCT) for severe SSc (7.1, SD 2.9); (3) phosphodiesterase inhibitors 5 for RP (7.3, SD 2.7). Agreement differed between Europe and non-Europe for the use of iloprost, bosentan, methotrexate, HSCT, and cyclophosphamide. Treatment availability could partially explain differential agreement for iloprost, bosentan, and HSCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In general, worldwide expert agreement on updated recommendations for treatment of SSc is high, supporting their value. Differences in agreement are partially explained by geographical area and treatment availability.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.181173","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T12:48:41Z","timestamp":1556714921000},"page":"249-254","source":"Crossref","is-referenced-by-count":31,"title":["Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5624-1415","authenticated-orcid":false,"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Balbir-Gurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"2020020109251863000_47.2.249.1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-455"},{"key":"2020020109251863000_47.2.249.2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5301\/jsrd.5000237","article-title":"Managing systemic sclerosis-related interstitial lung disease in the modern treatment era","volume":"2","author":"Volkmann","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2020020109251863000_47.2.249.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"2020020109251863000_47.2.249.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096677"},{"key":"2020020109251863000_47.2.249.5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","article-title":"Evidence-based management of systemic sclerosis: navigating recommendations and guidelines","volume":"46","author":"Pellar","year":"2017","journal-title":"Sem Arthritis Rheum"},{"key":"2020020109251863000_47.2.249.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203997"},{"key":"2020020109251863000_47.2.249.7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jsrd.5000256","article-title":"What have multicentre registries across the world taught us about the disease features of systemic sclerosis?","volume":"2","author":"Proudman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2020020109251863000_47.2.249.8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/AMEP.S115149","article-title":"Physicians\u2019 attitudes toward, use of, and perceived barriers to clinical guidelines: a survey among Swiss physicians","volume":"7","author":"Birrenbach","year":"2016","journal-title":"Adv Med Educ Pract"},{"key":"2020020109251863000_47.2.249.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"2020020109251863000_47.2.249.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101262"},{"key":"2020020109251863000_47.2.249.11","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.5301\/jsrd.5000230","article-title":"EUSTAR registration impacts favourably on clinical practice","volume":"2","author":"Vidal","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2020020109251863000_47.2.249.12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud\u2019s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Sem Arthritis Rheum"},{"key":"2020020109251863000_47.2.249.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2020020109251863000_47.2.249.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.9.1038"},{"key":"2020020109251863000_47.2.249.15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/BOR.0000000000000541","article-title":"Hematopoietic stem-cell transplantation in systemic sclerosis: an update","volume":"30","author":"Spierings","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2020020109251863000_47.2.249.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.015263"},{"key":"2020020109251863000_47.2.249.17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5301\/jsrd.5000234","article-title":"Controversies on the use of steroids in systemic sclerosis","volume":"2","author":"Herrick","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2020020109251863000_47.2.249.18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5301\/jsrd.5000211","article-title":"Systemic sclerosis-related calcinosis","volume":"1","author":"Herrick","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2020020109251863000_47.2.249.19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5301\/jsrd.5000207","article-title":"Emerging strategies for treatment of systemic sclerosis","volume":"1","author":"Khanna","year":"2016","journal-title":"J Scleroderma Relat Disord"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.181173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T12:25:44Z","timestamp":1580559944000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.3899\/jrheum.181173"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.181173","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}